Properties of the phi meson at high temperatures and densities

We calculate the spectral density of the phi meson in a hot bath of nucleons and pions using a general formalism relating self-energy to the forward scattering amplitude (FSA). In order to describe the low energy FSA, we use experimental data along with a background term. For the high energy FSA, a Regge parameterization is employed. We verify the resulting FSA using dispersion techniques. We find that the position of the peak of the spectral density is slightly shifted from its vacuum position and that its width is considerably increased. The width of the spectral density at a temperature of 150 MeV and at normal nuclear density is more than 90 MeV.Comment: 4 pages, 5 figures, Poster presented at Quark Matter 200

Is it possible to formulate least action principle for dissipative systems?

A longstanding open question in classical mechanics is to formulate the least action principle for dissipative systems. In this work, we give a general formulation of this principle by considering a whole conservative system including the damped moving body and its environment receiving the dissipated energy. This composite system has the conservative Hamiltonian $H=K_1+V_1+H_2$ where $K_1$ is the kinetic energy of the moving body, $V_1$ its potential energy and $H_2$ the energy of the environment. The Lagrangian can be derived by using the usual Legendre transformation $L=2K_1+2K_2-H$ where $K_2$ is the total kinetic energy of the environment. An equivalent expression of this Lagrangian is $L=K_1-V_1-E_d$ where $E_d$ is the energy dissipated by the friction from the moving body into the environment from the beginning of the motion. The usual variation calculus of least action leads to the correct equation of the damped motion. We also show that this general formulation is a natural consequence of the virtual work principle.Comment: 11 pages, no figur

Progress in Classical and Quantum Variational Principles

We review the development and practical uses of a generalized Maupertuis least action principle in classical mechanics, in which the action is varied under the constraint of fixed mean energy for the trial trajectory. The original Maupertuis (Euler-Lagrange) principle constrains the energy at every point along the trajectory. The generalized Maupertuis principle is equivalent to Hamilton's principle. Reciprocal principles are also derived for both the generalized Maupertuis and the Hamilton principles. The Reciprocal Maupertuis Principle is the classical limit of Schr\"{o}dinger's variational principle of wave mechanics, and is also very useful to solve practical problems in both classical and semiclassical mechanics, in complete analogy with the quantum Rayleigh-Ritz method. Classical, semiclassical and quantum variational calculations are carried out for a number of systems, and the results are compared. Pedagogical as well as research problems are used as examples, which include nonconservative as well as relativistic systems

Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates

Increases in expression of ADAM10 and ADAM17 genes and proteins have been evaluated, but not validated as cancer biomarkers. Specific enzyme activities better reflect enzyme cellular functions, and might be better biomarkers than enzyme genes or proteins. However, no high throughput assay is available to test this possibility. Recent studies have developed the high throughput real-time proteolytic activity matrix analysis (PrAMA) that integrates the enzymatic processing of multiple enzyme substrates with mathematical-modeling computation. The original PrAMA measures with significant accuracy the activities of individual metalloproteinases expressed on live cells. To make the biomarker assay usable in clinical practice, we modified PrAMA by testing enzymatic activities in cell and tissue lysates supplemented with broad-spectrum non-MP enzyme inhibitors, and by maximizing the assay specificity using systematic mathematical-modeling analyses. The modified PrAMA accurately measured the absence and decreases of ADAM10 sheddase activity (ADAM10sa) and ADAM17sa in ADAM10-/- and ADAM17-/- mouse embryonic fibroblasts (MEFs), and ADAM10- and ADAM17-siRNA transfected human cancer cells, respectively. It also measured the restoration and inhibition of ADAM10sa in ADAM10-cDNA-transfected ADAM10-/- MEFs and GI254023X-treated human cancer cell and tissue lysates, respectively. Additionally, the modified PrAMA simultaneously quantified with significant accuracy ADAM10sa and ADAM17sa in multiple human tumor specimens, and showed the essential characteristics of a robust high throughput multiplex assay that could be broadly used in biomarker studies. Selectively measuring specific enzyme activities, this new clinically applicable assay is potentially superior to the standard protein- and gene-expression assays that do not distinguish active and inactive enzyme forms